Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $9

Benzinga Newsdesk www.benzinga.com Neutral 49.2%

Neg 0% Neu 49.2% Pos 0%

Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $10 to $9.